New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 5, 2012
10:21 EDTARRYArray BioPharma to present data at ASH meeting
Array BioPharma announced that data will be presented on two drug candidates, ARRY-520, a KSP inhibitor, and ARRY-614, a dual p38/Tie2 inhibitor, at the 2012 Annual Meeting of the American Society of Hematology. Array will also hold a conference call today at 4:30 p.m. ET, to review the abstracts. Early data from the ongoing combination with carfilzomib is reported in an abstract. In the ARRY-614 abstract, new formulation demonstrated improved bioavailability and inter-patient variability with in th ongoing study in low or intermediate-1 risk Myelodysplastic Syndromes, Array said. In its prior study in a similar population, the company said it observed a 38% response rate for hematologic improvement in patients receiving the highest dose of our prior formulation. At this dose, ARRY-614 demonstrated multilineage hematologic improvement in 67% of the responders, improving two or more cytopenia. Array intends to meet with the FDA to discuss the development plan to support registration.
News For ARRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2015
10:11 EDTARRYHigh option volume stocks
Subscribe for More Information
September 28, 2015
12:25 EDTARRYArray data have positive read-through to Phase 3 trial, says Piper Jaffray
Subscribe for More Information
12:22 EDTARRYArray says binimetinib-encorafenib combo shows differentiated tolerability
Subscribe for More Information
September 25, 2015
08:39 EDTARRYArray BioPharma to host conference call
Conference call to discuss preliminary results from two melanoma trials and a colorectal cancer trial will be held on September 28 at 9 am. Webcast Link
September 24, 2015
10:25 EDTARRYOptions with decreasing implied volatility
Options with decreasing implied volatility: HRTX ATML ARRY YY OVTI RHT KMX

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use